Bank Pictet & Cie Europe AG Has $428,000 Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Bank Pictet & Cie Europe AG decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 42.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,902 shares of the medical research company's stock after selling 4,329 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in Edwards Lifesciences were worth $428,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Prosperity Consulting Group LLC raised its position in Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock valued at $289,000 after buying an additional 134 shares during the last quarter. Abacus Planning Group Inc. grew its stake in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after acquiring an additional 140 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after purchasing an additional 145 shares during the last quarter. Kera Capital Partners Inc. lifted its position in shares of Edwards Lifesciences by 5.0% in the first quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock worth $224,000 after purchasing an additional 148 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its position in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after purchasing an additional 152 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the topic of several recent research reports. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Citigroup reissued a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and a consensus price target of $80.20.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.22 during midday trading on Wednesday, hitting $73.49. 529,640 shares of the company were exchanged, compared to its average volume of 4,518,936. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The firm has a market capitalization of $43.11 billion, a P/E ratio of 10.50, a PEG ratio of 3.77 and a beta of 1.12. The firm's 50 day moving average price is $74.77 and its two-hundred day moving average price is $72.96. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the business posted $0.66 earnings per share. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president now directly owns 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This trade represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,898 shares of company stock worth $3,796,154 in the last ninety days. 0.34% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.